
Neuspera Gains Medicare Reimbursement Parity for Sacral Neuromodulation
The Centers for Medicare & Medicaid Services has confirmed that the Neuspera integrated sacral neuromodulation system will receive the same reimbursement level as legacy implantable devices under the proposed 2027 payment rule, marking a significant shift in the competitive landscape for urinary urge incontinence treatments.






















